Navigation Links
Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa
Date:5/13/2009

HORSHAM, Pa., May 13 /PRNewswire/ -- Data from a study of managed-care cancer patients receiving chemotherapy and newly treated with erythropoiesis-stimulating agents (ESAs) found that the cumulative ESA cost with Epoetin alfa (EPO) was 29 percent lower than treatment with darbepoetin alfa (DARB). The analysis, published in the Spring issue of the Journal of Medical Economics, was sponsored by Centocor Ortho Biotech Services, LLC.

The retrospective cohort study of 10,928 patients investigated the current real-world dosing patterns and associated ESA costs in an adult cancer chemotherapy population. The data showed that the cumulative ESA cost was $4,321 for patients receiving EPO vs. $6,089 for DARB patients (p<0.0001). The dose ratio was 255 units of EPO to 1 microgram (mcg) of DARB. The authors stated these findings are consistent with dose ratios from studies of randomized clinical trials and other observational studies.

The EPO:DARB dose ratio often is used to compare the relative utilization of EPO and DARB because EPO is measured in International Units and DARB is measured in micrograms. It is based on the agents' cumulative treatment doses and often is used for reimbursement purposes by payers.

"Information regarding the dose ratio between EPO and DARB in real-world settings is important to ensure healthcare resources are used efficiently," said Francis Vekeman, M.A., Senior Economist, Groupe d'analyse, Ltee, Montreal, Quebec, Canada. "Managed care organizations may find it informative that our retrospective analysis reported a dose ratio of EPO to DARB of 255:1, which was associated with lower ESA costs for patients receiving EPO in the managed care setting."

About the Study

Vekeman et al. conducted a retrospective cohort study of medical claims data from the PharMetrics Patient-Centric database of approximately 85 health plans from January
'/>"/>

SOURCE Centocor Ortho Biotech Products, L.P.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Retrospective study analyzes expenses of osteoporosis-related fracture over 3 years
2. Study, meta-analysis examine factors associated with death from heatstroke
3. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
6. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
7. Physical Therapist Provides Injury Analysis for Fantasy Football
8. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
9. Meta-Analysis of Blood Phe Levels and Clinical Outcomes in PKU Published
10. OCS and Press Ganey Partner to Create Joint Analysis of Outcomes and Satisfaction
11. New Analysis Underscores Legality of Physician Ranking and Public Reporting Systems When Used by Health Insurers to Improve Health Care Quality

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)... form between brain cells almost immediately as an...shed this week in Nature . Led by researchers at ...y involved detailed observations of the rewiring p... learning. , The researchers studied mice as the...ed. They observed rapid growth of structures that ...
(Date:11/29/2009)...equals a $41,000 pay raise, researchers say , ...hological therapy may be much more effective at ma...a lottery prize, suggests an English study. , R...o provided information about their mental well-bei... $1,329 course of therapy was so significant that ...
(Date:11/29/2009)...care,s uncertain future and rising costs open the ...dable Acupuncture Scottsdale answers the call. , ...-- Affordable Acupuncture, LLC opened in Scottsdal...h enthusiasm and gratitude. Its increasing popular...ngs, need and cost. "As far as I’m con...
(Date:11/28/2009)...r change after 30-minute psychosocial intervention...hDay News) -- A program that gets persistent drunk...ngerous behavior may lead to significant and long-...new study included 184 men and women with two or m...andomly assigned to one of two interventions. The ...
(Date:11/27/2009)...wire-FirstCall/ -- GSI Group Inc. (Pink Sheets: GS...ology products and semiconductor systems, today an...areholders has been scheduled for Friday, April 30... be announced in due course. As previously announ...m Stephen Bershad, a holder of greater than ten pe...
Breaking Medicine News(10 mins):Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Psychotherapy Can Boost Happiness More Than Money: Study 2Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:GSI Group Calls Shareholders Meeting 2
...have launched a public awareness campaign warning ...ess-skilled non-physicians performing the procedur...going procedures like Botox injections, laser hair...n some cases. The American Society of Derma...
... lifestyles and environmental changes have caused ...e. They represent 17% of the childhood cancer case... between 1978 and 1997 in 15 European countries we... the age of 14. Majority of the childhood canc...
...d’, a new oral drug that is being developed for mu...he new study has suggests that the experimental dr...ts with relapsing multiple sclerosis. It was also ...patients with MS the first effective treatment in ...
... have more urinary problems than white men, but ar...ology study that was conducted on over 8,000 men h...ology journal BJU International, states that South... in Leicestershire, UK, were randomly selected fro...
...t medical trusts facing major losses to outsource ... one million pounds a year.// Around 60 speci...sourcing. Hospitals in Leeds are reported to be fa...have been fiercely criticised by union leaders, MP...
...gram developed by researchers now at the Universit...e used to study how individuals with sickle cell d...erited blood disorder.// The $2.9 million f...to educate them about pain management and provide ...
Other Medicine News:Health News:Campaign Against Cosmetic Surgeries Performed By Less-Skilled Non-physicians Launched 2Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2Health News:An Experimental New Drug Might Be Effective In Treating MS 2Health News:South Asian Men Have More Urinary Problems Than White Men 2Health News:Leeds Hospitals to Outsource Medical Transcription Work to India 2Health News:Computer May Improve Pain Relief for Sickle Cell Patients 2
(Date:11/28/2009)... Siemens Healthcare redefines prod...(Total imaging matrix) technology and with its new...technologies are introduced in the new MAGNETOM &#...ra* 3T scanners at the 95th Scientific Assembly an...rth America (RSNA) from November 29 to December 3 ...
(Date:11/26/2009)...outh Africa, Nov. 26 The 2009 Fros...Award in the Generic Pharmaceutical Market is pres...(Logo: http://www.newscom.com/cgi-bin/prnh/200811...d, the following criteria were used to benchmark C... growth strategy and implementation, degree of inn...
(Date:11/25/2009)...ov. 25 Pharmasset, Inc. ...company committed to discovering, developing and c...ns, reported financial results for the fiscal year...harmasset held $58.4 million in cash, cash equival...Update and 2009 Highlights ,, RG7128 ,, ...
Breaking Medicine Technology:Siemens Introduces Its New Power Couple at RSNA 2009 2Siemens Introduces Its New Power Couple at RSNA 2009 3Siemens Introduces Its New Power Couple at RSNA 2009 4Siemens Introduces Its New Power Couple at RSNA 2009 5Siemens Introduces Its New Power Couple at RSNA 2009 6Siemens Introduces Its New Power Couple at RSNA 2009 7Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10Synthetech Announces Fiscal 2009 Results 47845 1Synthetech Announces Fiscal 2009 Results 47845 2Synthetech Announces Fiscal 2009 Results 47845 3Synthetech Announces Fiscal 2009 Results 47845 4Synthetech Announces Fiscal 2009 Results 47845 5Synthetech Announces Fiscal 2009 Results 47845 6Consumer Watchdog Praises Insurance Commissioner Poizner for Health Insurance Rescission Rules Pans Schwarzenegger Administration for Failure to Regu 47842 1Consumer Watchdog Praises Insurance Commissioner Poizner for Health Insurance Rescission Rules Pans Schwarzenegger Administration for Failure to Regu 47842 2Consumer Watchdog Praises Insurance Commissioner Poizner for Health Insurance Rescission Rules Pans Schwarzenegger Administration for Failure to Regu 47842 3Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 1Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 2
...s Phase 3 Plans with FDA, PRINCETON, N.J., Sept. ...t successfully completed two key clinical trials i... low-dose, once-weekly,contraceptive patch, which ... AG-200-15. The Phase 2b safety and efficacy study...n suppression, cycle control and safety. The,pharm...
...Sept. 3 A sub-analysis of,the TRITON-TIMI 38 clin...mpared with clopidogrel significantly reduced the ...t vs. 9.7 percent, p<0.0001), regardless,of wh...tery-opening,procedure known as percutaneous coron...neously during the longer-term maintenance phase. ...
Other Medicine Technology:Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6
HDL Cholesterol (PEG)
Cholesterol/HDL
HDL-Cholesterol Direct Reagent
HDL Cholesterol
Medicine Products: